Dr. Amita Patnaik, MD
Claim this profileSouth Texas Accelerated Research Therapeutics
Expert in Tumors
Studies Solid Tumors
18 reported clinical trials
25 drugs studied
About Amita Patnaik, MD
Education:
- Obtained MD (Doctor of Medicine) with honors from the University of Toronto, Canada.
- Completed Residency in Internal Medicine and Fellowship in Medical Oncology at the University of Toronto.
- Advanced Research Fellowship in Anticancer-drug Development at the University of Texas Health Science Center at San Antonio.
Experience:
- Co-founder of South Texas Accelerated Research Therapeutics (START) and serves as its Co-Director of Clinical Research.
- Recognized for pioneering the development of over 20 new anticancer drugs approved by the U.S. FDA.
- Authored over 90 peer-reviewed publications in top-tier journals, including The Lancet and Cancer Discovery.
- Recipient of numerous awards, including the San Antonio Business Journal's "40 under 40" and the Healthcare Heroes Award.
Area of expertise
1Tumors
Global LeaderStage IV
Stage III
HER2 negative
2Solid Tumors
Stage IV
Stage III
metastatic
Affiliated Hospitals
Clinical Trials Amita Patnaik, MD is currently running
INV-1120 + Pembrolizumab
for Advanced Cancer
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.
Recruiting1 award Phase 110 criteria
SGN-PDL1V
for Cancer
This trial is testing a new drug, SGN-PDL1V, alone and with pembrolizumab, in patients with advanced solid tumors. The goal is to see if these treatments are safe and effective. SGN-PDL1V targets cancer cells directly, while pembrolizumab helps the immune system fight the cancer.
Recruiting1 award Phase 1
More about Amita Patnaik, MD
Clinical Trial Related4 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Amita Patnaik, MD has experience with
- Pembrolizumab
- Nab-sirolimus
- UCT-03-008
- Niraparib
- SGN-B6A
- Dostarlimab
Breakdown of trials Amita Patnaik, MD has run
Tumors
Solid Tumors
Cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Amita Patnaik, MD specialize in?
Amita Patnaik, MD focuses on Tumors and Solid Tumors. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are Stage III.
Is Amita Patnaik, MD currently recruiting for clinical trials?
Yes, Amita Patnaik, MD is currently recruiting for 11 clinical trials in San Antonio Texas. If you're interested in participating, you should apply.
Are there any treatments that Amita Patnaik, MD has studied deeply?
Yes, Amita Patnaik, MD has studied treatments such as Pembrolizumab, nab-sirolimus, UCT-03-008.
What is the best way to schedule an appointment with Amita Patnaik, MD?
Apply for one of the trials that Amita Patnaik, MD is conducting.
What is the office address of Amita Patnaik, MD?
The office of Amita Patnaik, MD is located at: South Texas Accelerated Research Therapeutics, San Antonio, Texas 78229 United States. This is the address for their practice at the South Texas Accelerated Research Therapeutics.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.